Managing IAV-S: New Data Show Significant Improvement in Average Daily Gain (ADG) and Mortality


Historically, uncomplicated IAV-S has been shown to lead to an estimated loss of more than $3 per pig; when present with concurrent infections, the loss associated with IAV-S can be greater than $10 per pig.1,*

Recent data suggest that coinfection can lead to even greater economic loss:
  • When IAV-S and porcine reproductive and respiratory syndrome (PRRS) simultaneously infect pigs in late nursery, losses can average $18 per pig2
Until recently, there have been few tools commercially available to provide protection against influenza and its impact on the health and performance of growing pigs.

Influenza A virus in swine (IAV-S) is costly to the swine industry, especially when coinfection with other respiratory pathogens is present. The implications of these coinfections are reflected in both higher mortality rates and reduction in ADG.

Production and performance with Ingelvac Provenza®
Ingelvac Provenza® is a live attenuated influenza vaccine (LAIV) that can be given to pigs as early as day one via intranasal administration. It has recently been evaluated in 2 commercial 5000-sow flows.


CASE STUDY 1:
ADG, feed conversion ratio (FCR), average market weight, and days to market3

Objective: To assess measures of growing pig performance in a 2-sow farm flow (5000 total sows) from a large commercial swine operation in the midwestern United States before and after the introduction of Ingelvac Provenza®.

Investigators: J. Morgan, K. Kovach, C. Goodell, K.M. Cicconi-Hogan

Method: Observe measurable differences in key performance indicators (KPIs) (ADG, FCR, average market weight, and days to market) after vaccination with Ingelvac Provenza®.

Key takeaway: Pigs vaccinated with Ingelvac Provenza® went to market nearly 7 days sooner, with an increase in average market weight of over 3 lb.

Key takeaway: Pigs vaccinated with Ingelvac Provenza® went to market nearly 7 days sooner, with an increase in average market weight of over 3 lb.


CASE STUDY 2:
ADG and mortality4

Objective: To assess the performance of growing pigs in an IAV-endemic commercial 5000-sow farm flow before and after the implementation of Ingelvac Provenza®.

Investigators: E. Mondaca-Fernandez, E. Lowe, C. Goodell, K.M. Cicconi-Hogan

Method: Use summary nursery and finishing closeout data to compare ADG and mortality prior to and after vaccination with Ingelvac Provenza®.

Key takeaway: Significant improvements of 0.10 lb/day wean to finish ADG and mortality reduction of 0.95% were observed after the initiation of Ingelvac Provenza® in a flow previously diagnosed as endemic for IAV-S.

Key takeaway: Significant improvements of 0.10 lb/day wean to finish ADG and mortality reduction of 0.95% were observed after the initiation of Ingelvac Provenza® in a flow previously diagnosed as endemic for IAV-S.


Building a strong immune foundation throughout the herd.

These studies have shown that vaccination with Ingelvac Provenza® can be a valuable tool in current IAV-S protocols, and positive vaccine impact can be measured by standard performance targets.

For more information on how Ingelvac Provenza® can help establish a strong foundation for respiratory health, visit IngelvacProvenza.com

*Above baseline

Disclaimer

WELCOME TO INGELVACPROVENZA.COM

Are you located within the United States of America?
ARE YOU A VETERINARIAN?

This is a required field

This website is an international information resource intended for veterinarians who are interested in information about Ingelvac Provenza® and influenza A virus in swine.

While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product label may not be the same in different countries.

INGELVAC Provenza® IS ONLY CURRENTLY LICENCED IN THE UNITED STATES OF AMERICA. Information on this website is derived from the product label in the USA.

By checking the box below, you are declaring and confirming that you are a veterinarian professional and that you have read and understood this disclaimer.

You must accept the terms and conditions and data policy to enter the website

Ingelvac Provenza is a trademark of Boehringer Ingelheim Vetmedica GmbH. © 2018 Boehringer Ingelheim Vetmedica, Inc.